Ventrus Biosciences Inc (VTUS.OQ)

VTUS.OQ on NASDAQ Stock Exchange Capital Market

1.51USD
9 Jul 2014
Price Change (% chg)

$0.18 (+13.53%)
Prev Close
$1.33
Open
$1.30
Day's High
$1.55
Day's Low
$1.30
Volume
183,973
Avg. Vol
116,294
52-wk High
$4.69
52-wk Low
$0.85

VTUS.OQ

Chart for VTUS.OQ

About

Ventrus Biosciences, Inc. (Ventrus) is a development-stage specialty pharmaceutical company. The Company is focused on the development of late-stage and pre-clinical prescription drugs and biologics, for gastrointestinal disorders. The Company’s product portfolio consists of two late stage assets: VEN 307 (topical diltiazem) for... (more)

Overall

Beta: 0.10
Market Cap (Mil.): $31.00
Shares Outstanding (Mil.): 23.40
Dividend: --
Yield (%): --

Financials

  VTUS.OQ Industry Sector
P/E (TTM): -- 35.12 35.56
EPS (TTM): -0.96 -- --
ROI: -68.62 18.93 18.20
ROE: -68.62 19.73 19.10
Search Stocks

Ventrus shares slump after anal fissure drug fails in trial

- Ventrus Biosciences Inc's shares plunged 66 percent after the company said its lead experimental treatment for anal fissures failed to reduce pain compared with a placebo in a second late-stage trial.

12 Feb 2014

UPDATE 1-Ventrus shares slump after anal fissure drug fails in trial

(Updates share movement; adds details and analyst comment)

12 Feb 2014

CORRECTED-Ventrus' anal fissure drug fails in trial, shares slump

(Corrects stock's Tuesday close in last paragraph to $4.38 from $4.69)

12 Feb 2014

Competitors

  Price Change
Kyowa Hakko Kirin Co Ltd (4151.T) ¥1,396 +3.00

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: Pechala's Reports
$15.00
Provider: Reuters Investment Profile
$20.00
Provider: Pechala's Reports
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks